Proteome-based plasma biomarkers for Alzheimer's disease.
暂无分享,去创建一个
S. Lovestone | J. Powell | C. Shaw | S. Tabrizi | R. Brown | F. Rijsdijk | G. Hamilton | M. Ward | M. Thambisetty | A. Hye | J. Powell | S. Lynham | M. Causevic | J. Campbell | H. Byers | C. Hooper | S. Banner | C. Shaw | C. Foy | M. Poppe | N. Archer | P. Sham | M. Poppe | James Campbell | P. Sham | R. Brown | Richard G. Brown | Abdul Hye | Gillian Hamilton | J. Powell | C. Shaw
[1] T. Berzin,et al. Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.
[2] Charles D. Smith,et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity , 2007, NeuroMolecular Medicine.
[3] G. Bernardi,et al. Differential post‐translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid , 2006, Proteomics.
[4] Jan-Gowth Chang,et al. Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.
[5] David A Bennett,et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. , 2005, Clinical chemistry.
[6] A. Yocum,et al. Effect of immunoaffinity depletion of human serum during proteomic investigations. , 2005, Journal of proteome research.
[7] Raquel E. Gur,et al. The Use of Biomarkers in the Elderly: Current and Future Challenges , 2005, Biological Psychiatry.
[8] W. Barrett,et al. Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.
[9] Kelvin H. Lee,et al. Complement Protein Isoforms in CSF as Possible Biomarkers for Neurodegenerative Disease , 2005, Disease markers.
[10] R. T. Smith,et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] A. Edwards,et al. Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.
[12] J. Gilbert,et al. Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.
[13] J. Ott,et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.
[14] M. D'Andrea. Add Alzheimer's disease to the list of autoimmune diseases. , 2005, Medical hypotheses.
[15] S. Tam,et al. Depletion and fractionation technologies in plasma proteomic analysis , 2004, Expert review of proteomics.
[16] C. Turck,et al. Enhancing analytical access to low-abundant proteins in the human plasma proteome , 2004 .
[17] S. Rodríguez de Córdoba,et al. The human complement factor H: functional roles, genetic variations and disease associations. , 2004, Molecular immunology.
[18] Robyn H Guymer,et al. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.
[19] L. Almasy,et al. Genetic and environmental factors influencing the human factor H plasma levels , 2004, Immunogenetics.
[20] Kuo-Chen Chou,et al. Bio-support vector machines for computational proteomics , 2004, Bioinform..
[21] H. Möller,et al. Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity , 2004, Journal of Neural Transmission.
[22] Deborah Pinchev,et al. Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.
[23] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[24] S. Wisniewski,et al. Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment , 2003, Annals of neurology.
[25] Charles D. Smith,et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. , 2003, Neuromolecular medicine.
[26] R. Strohmeyer,et al. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain , 2002, Journal of Neuroimmunology.
[27] Alexander J. Rivest,et al. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Martini,et al. α2-Macroglobulin Deletion Polymorphism and Plasma Levels in Late Onset Alzheimer's Disease , 2002 .
[29] Alexander J. Rivest,et al. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] Constantin F. Aliferis,et al. Machine learning models for lung cancer classification using array comparative genomic hybridization , 2002, AMIA.
[31] J. Quigley,et al. A role for protease inhibitors in immunity of long-lived animals. , 2001, Advances in experimental medicine and biology.
[32] J. Rogers,et al. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. , 2000, Brain research. Molecular brain research.
[33] S. Russell,et al. Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] A. Hofman,et al. Is age-related maculopathy associated with Alzheimer's Disease? The Rotterdam Study. , 1999, American journal of epidemiology.
[35] H. Möller,et al. Oligoclonal bands and blood--cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. , 1999, Alzheimer disease and associated disorders.
[36] A. Hofman,et al. Is age-related maculopathy associated with Alzheimers disease? , 1998 .
[37] H. Hampel,et al. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. , 1995, Dementia.
[38] K. Mattila,et al. Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. , 1995, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.
[39] G. Mashour,et al. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. , 1994, Alzheimer disease and associated disorders.
[40] H. Wiśniewski,et al. Immunoglobulin G subclasses in older persons with Down syndrome , 1993, Journal of the Neurological Sciences.
[41] J. Bauer,et al. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. , 1992, Laboratory investigation; a journal of technical methods and pathology.
[42] U. Schreiter-Gasser,et al. Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices , 1991, FEBS letters.
[43] D. Newsome,et al. Macular degeneration and elevated serum ceruloplasmin. , 1986, Investigative ophthalmology & visual science.
[44] B. Reisberg,et al. The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.